The Austin, Texas–based company said Wednesday that FDA has cleared an Aries assay for group B streptococcus. It’s the third assay FDA has cleared for use with Luminex’s Aries systems.
The GBS assay has also received a CE-IVD marking. Luminex plans to launch additional Aries assays this year. Aries systems are meant to increase laboratory efficiency and ensure result accuracy.
Get the full story on our sister site, Medical Design & Outsourcing.